As global biotech investment patterns shift, investors are turning their eyes to Asia-Pacific. While China remains a powerhouse, emerging hubs like Singapore and South Korea are quickly gaining attention for their political stability, strong IP protection, and innovation-friendly policies.
Why are APAC biotech markets suddenly so appealing to investors? And how are these emerging hubs reshaping the future of global biotech innovation?
On Wealth Tracker, Hongbin Jeong speaks to Fabio La Mola, Partner at Bain & Company, to find out more.

The Agenda: Could fractional work be the new retirement plan for seniors?
11:24

The Big Story: MRT reliability hits record high in September. But are commuters feeling the difference?
18:31

What's Trending: Changi’s carpet controversy... Is Singapore overprotective of its airport?
15:10